Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.
about
Charge-Surrounded Pockets and Electrostatic Interactions with Small Ions Modulate the Activity of Retroviral Fusion ProteinsThe M-T Hook Structure Is Critical for Design of HIV-1 Fusion InhibitorsBroad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor SifuvirtideDiscovery of Critical Residues for Viral Entry and Inhibition through Structural Insight of HIV-1 Fusion Inhibitor CP621-652Structural Basis of Potent and Broad HIV-1 Fusion Inhibitor CP32MCrystal Structures of Beta- and Gammaretrovirus Fusion Proteins Reveal a Role for Electrostatic Stapling in Viral EntryRaman spectroscopic signatures of echovirus 1 uncoating.Grid-based molecular footprint comparison method for docking and de novo design: application to HIVgp41Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.DNA duplexes with hydrophobic modifications inhibit fusion between HIV-1 and cell membranes.Pharmacophore-based similarity scoring for DOCKMechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 PocketDNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity.Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.Significant differences in cell-cell fusion and viral entry between strains revealed by scanning mutagenesis of the C-heptad repeat of HIV gp41Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates.Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides.Computer-Aided Approaches for Targeting HIVgp41.Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 functionImmunization with hybrid proteins containing the membrane proximal external region of HIV-1.Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity.The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.Precisely Designed Isopeptide Bridge-Crosslinking Endows Artificial Hydrolases with High Stability and Catalytic Activity under Extreme Denaturing Conditions.
P2860
Q27666913-E6253264-6B78-41F2-960F-6073342B9948Q27671434-4AF41E64-77DE-4C01-BD77-6D7FE0C3EF63Q27676641-B6E0859C-F43E-4A15-97A5-12A015967949Q27678581-E9F18C5E-E6F8-4A7C-801F-3F654C99FC96Q27679547-07EABDF6-2AA6-4FDA-86B2-70847FA2662EQ27680387-188A1999-FDF2-4CB5-A1FE-DFA3A9EB6129Q30362789-06998788-9E94-4622-848F-8DCDB2CBB8D1Q33590499-3FA0908A-B125-4BEE-AC34-7006916827DAQ33713101-68F8C82A-14B3-4A6E-AE31-6D7C938CE9BEQ34189558-07A881DD-2D9C-41E7-B11C-4CA768BFC5E8Q34298481-7FEFBC70-123A-4554-97A5-BE8FD5388FE4Q34879200-D294CBEB-168E-4842-826B-73E24B0885D4Q35013407-BFA81983-DEB2-46E7-AF31-C24A9879DB45Q35641194-72E08E56-72FA-44C5-9E5E-97F397E9AEE7Q35866029-7ADE0C15-5525-4495-9AB9-306FE039DF32Q36334376-E66FECC7-9E38-41D0-85E6-42D37CD4B69EQ36390483-43F3F88A-94B0-4C0F-B692-A7353B944C2FQ37130524-509FB355-84EC-47C0-B642-9D4D02A89FB2Q37512905-9F76B287-7984-468A-A699-DE6E76FBC771Q37617455-0C6C61E6-A082-4DCE-96BA-FD0F787A4919Q37831811-0E5A4CA0-FB18-4AE7-B89F-870C0BEF6901Q38111393-C5FD5F3F-E01D-4F77-9297-A49C1D252F2EQ38632078-AC652787-8923-4DA8-A1CB-2DBEF6C15118Q39229789-626A716A-63F9-4299-B253-0FA5D9E78312Q39455561-67458C75-62D9-49C6-8DA9-31E0D5492A52Q39794156-2B407E59-D54A-4940-BCDC-5E21B1D004CEQ40141950-4F663F6F-AC61-4C36-A41A-E461BDF4C5A8Q40267838-718CCF84-F35E-4E71-A49E-A78A570B1E01Q42213760-7989B9F1-FB0A-4AD9-AA1B-147F3EC15AE4Q42717107-589DEFBE-8EB7-4AD8-A05A-F3A59E13A482Q42732016-6CB3FA41-7E0A-47C5-B5B0-EDCC064B2084Q47882583-5474B913-28C1-4C40-8170-C654BED035DB
P2860
Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Conserved salt bridge between ...... or virus entry and inhibition.
@en
Conserved salt bridge between ...... or virus entry and inhibition.
@nl
type
label
Conserved salt bridge between ...... or virus entry and inhibition.
@en
Conserved salt bridge between ...... or virus entry and inhibition.
@nl
prefLabel
Conserved salt bridge between ...... or virus entry and inhibition.
@en
Conserved salt bridge between ...... or virus entry and inhibition.
@nl
P2093
P2860
P356
P1433
P1476
Conserved salt bridge between ...... or virus entry and inhibition.
@en
P2093
Asim K Debnath
Jingjing Li
Shuwen Liu
Zhonghua Liu
P2860
P304
11129-11139
P356
10.1128/JVI.01060-08
P407
P50
P577
2008-09-03T00:00:00Z